Právnická fakulta Univerzity Mateja Bela - oficiálna stránka - Právnická fakulta Univerzity Mateja Bela v Banskej Bystrici Vás pozýva na online sériu súdnych procesov, ktoré otriasli dejinami Československa naprieč 20. storočím. Jednotlivé
![Alexandra JUNGOVA | Medical Doctor | M.D., Ph.D. | Fakultní nemocnice Plzeň, Pilsen | FN Plzeň | Hematologicko onkologické oddělení | Research profile Alexandra JUNGOVA | Medical Doctor | M.D., Ph.D. | Fakultní nemocnice Plzeň, Pilsen | FN Plzeň | Hematologicko onkologické oddělení | Research profile](https://i1.rgstatic.net/ii/profile.image/278399483432964-1443387017676_Q512/Alexandra-Jungova.jpg)
Alexandra JUNGOVA | Medical Doctor | M.D., Ph.D. | Fakultní nemocnice Plzeň, Pilsen | FN Plzeň | Hematologicko onkologické oddělení | Research profile
MACHINE LEARNING FOR CLASSIFICATION OF AN ERODING SCARP SURFACE USING TERRESTRIAL PHOTOGRAMMETRY WITH NIR AND RGB IMAGERY
![PDF) Survival Benefit of Ixazomib, Lenalidomide and Dexamethasone (IRD) Over Lenalidomide and Dexamethasone (Rd) in Relapsed and Refractory Multiple Myeloma Patients in Routine Clinical Practice PDF) Survival Benefit of Ixazomib, Lenalidomide and Dexamethasone (IRD) Over Lenalidomide and Dexamethasone (Rd) in Relapsed and Refractory Multiple Myeloma Patients in Routine Clinical Practice](https://i1.rgstatic.net/publication/343461775_Survival_Benefit_of_Ixazomib_Lenalidomide_and_Dexamethasone_IRD_Over_Lenalidomide_and_Dexamethasone_Rd_in_Relapsed_and_Refractory_Multiple_Myeloma_Patients_in_Routine_Clinical_Practice/links/5f2b62f8299bf13404a5c971/largepreview.png)
PDF) Survival Benefit of Ixazomib, Lenalidomide and Dexamethasone (IRD) Over Lenalidomide and Dexamethasone (Rd) in Relapsed and Refractory Multiple Myeloma Patients in Routine Clinical Practice
![PDF) Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice PDF) Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice](https://i1.rgstatic.net/publication/348533101_Survival_benefit_of_ixazomib_lenalidomide_and_dexamethasone_IRD_over_lenalidomide_and_dexamethasone_Rd_in_relapsed_and_refractory_multiple_myeloma_patients_in_routine_clinical_practice/links/6004198aa6fdccdcb85c4fe7/largepreview.png)